Agentix (AGTX) Stock Overview
A clinical development stage company, focuses on the development and commercialization of novel therapeutics to treat metabolic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
AGTX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Agentix Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.02 |
| 52 Week High | US$0.055 |
| 52 Week Low | US$0.014 |
| Beta | 0.77 |
| 1 Month Change | 0% |
| 3 Month Change | 17.65% |
| 1 Year Change | -48.39% |
| 3 Year Change | -72.03% |
| 5 Year Change | -98.00% |
| Change since IPO | -99.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| AGTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 0.4% | -0.2% |
| 1Y | -48.4% | 36.4% | 11.9% |
Return vs Industry: AGTX underperformed the US Biotechs industry which returned 37.1% over the past year.
Return vs Market: AGTX underperformed the US Market which returned 12% over the past year.
Price Volatility
| AGTX volatility | |
|---|---|
| AGTX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: AGTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine AGTX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | n/a | Rehan Huda | www.agentixcorp.com |
Agentix Corp., a clinical development stage company, focuses on the development and commercialization of novel therapeutics to treat metabolic diseases in the United States. It develops AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver diseases. The company has licensing agreement with National Health Research Institute and Research Triangle Institute.
Agentix Corp. Fundamentals Summary
| AGTX fundamental statistics | |
|---|---|
| Market cap | US$801.34k |
| Earnings (TTM) | -US$417.49k |
| Revenue (TTM) | n/a |
Is AGTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AGTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$417.49k |
| Earnings | -US$417.49k |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.01 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -10.2% |
How did AGTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/19 21:04 |
| End of Day Share Price | 2026/08/25 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Agentix Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.